Ep 184 Must Know Drug Interactions in Emergency Medicine
June 27, 2023
We miss potentially dangerous and even lethal drug interactions in EM more often than we realize. In this main episode EM Cases podcast with Dr....
Anton Helman
Andexanet Alfa Vs. Four-Factor PCC: Is Andexanet Alfa Worth The Hype?
February 28, 2022
Background: Oral factor Xa inhibitors (FXi) have been associated with major and fatal bleeding events, including intracranial hemorrhage (ICH). In randomized controlled trials, both rivaroxaban...
Marco Torres
EM Quick Hits 8 Lemierre’s Syndrome, Clonidine Toxicity, Routine Coag Panel, Anticoagulation Reversal, Mechanical CPR
September 10, 2019
Anand Swaminathan on Lemierre's syndrome, Emily Austin on clonidine toxicity, Brit Long on myths of routine coagulation panel testing, Hans Rosenberg and Michael Ho on reversal...
Safety of PE Treatment with Rivaroxaban
August 31, 2017
Background: The simplified PE Severity Index (sPESI) is one of several validated prognostic tools for acute pulmonary embolism (PE). The European Society of Cardiology recommended the...
EM Cases Best of 2016 Top Ten
January 3, 2017
The year 2016 was one of the most productive one in the entire 7 year history of EM Cases with a total of 29 podcast...
Best Case Ever 51 – Anticoagulants and GI Bleed with Walter Himmel
November 8, 2016
In anticipation of Episode 88 and 89: DOACs Use, Misuse and Reversal with the president of Thrombosis Canada and world renowned thrombosis researcher Dr. Jim...